tiprankstipranks
Advertisement
Advertisement

TAK Stock Latest News

Abivax appoints Michael Nesrallah as chief commercial officer
The FlyAbivax appoints Michael Nesrallah as chief commercial officer
4d ago
TAK
ABVX
Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda
PremiumThe Fly
Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda
4d ago
TAK
AXSM
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
PremiumThe Fly
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
6d ago
JNJ
TAK
Alumis price target raised to $55 from $50 at Oppenheimer
PremiumThe Fly
Alumis price target raised to $55 from $50 at Oppenheimer
6d ago
JNJ
TAK
Takeda announces new data from Phase 3 studies of TAK-279
PremiumThe Fly
Takeda announces new data from Phase 3 studies of TAK-279
7d ago
TAK
Alkermes price target lowered to $43 from $45 at Piper Sandler
PremiumThe FlyAlkermes price target lowered to $43 from $45 at Piper Sandler
13d ago
TAK
ALKS
Takeda’s Long-Term Psoriatic Arthritis Trial Could Reshape TAK’s Immunology Outlook
Premium
Company Announcements
Takeda’s Long-Term Psoriatic Arthritis Trial Could Reshape TAK’s Immunology Outlook
17d ago
TAK
Takeda Advances Dual-Therapy Ulcerative Colitis Study, Keeping Entyvio in the GI Spotlight
Premium
Company Announcements
Takeda Advances Dual-Therapy Ulcerative Colitis Study, Keeping Entyvio in the GI Spotlight
18d ago
TAK
Takeda’s Dual-Drug Crohn’s Study Could Reframe Entyvio’s Role in IBD Portfolios
PremiumCompany Announcements
Takeda’s Dual-Drug Crohn’s Study Could Reframe Entyvio’s Role in IBD Portfolios
18d ago
TAK
Takeda Tracks Real-World Safety of Alunbrig in Japanese Lung Cancer Patients
PremiumCompany Announcements
Takeda Tracks Real-World Safety of Alunbrig in Japanese Lung Cancer Patients
19d ago
TAK
Takeda’s New South Korea HAE Study Aims to Cement Takhzyro’s Real World Edge
PremiumCompany Announcements
Takeda’s New South Korea HAE Study Aims to Cement Takhzyro’s Real World Edge
23d ago
TAK
Takeda’s EXPLORHAE HAE Study in Egypt: Real‑World Data With Long‑Term Investor Upside
PremiumCompany Announcements
Takeda’s EXPLORHAE HAE Study in Egypt: Real‑World Data With Long‑Term Investor Upside
23d ago
TAK
Takeda Deepens Real-World Evidence in Ultra-Rare cTTP With New ADAMTS13 Study
PremiumCompany AnnouncementsTakeda Deepens Real-World Evidence in Ultra-Rare cTTP With New ADAMTS13 Study
23d ago
TAK
Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel
Premium
Company Announcements
Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel
27d ago
TAK
Takeda’s TAK-861 Narcolepsy Study Moves Forward, Extending the Long-Term Bet on Sleep Disorders
Premium
Company Announcements
Takeda’s TAK-861 Narcolepsy Study Moves Forward, Extending the Long-Term Bet on Sleep Disorders
1M ago
TAK
Takeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play
PremiumCompany Announcements
Takeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play
1M ago
TAK
Takeda Maps Narcolepsy in Spain: What This New Epidemiology Study Means for Investors
PremiumCompany Announcements
Takeda Maps Narcolepsy in Spain: What This New Epidemiology Study Means for Investors
1M ago
TAK
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
PremiumThe Fly
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
1M ago
TAK
PTGX
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
PremiumThe Fly
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
1M ago
TAK
PTGX
Takeda Expands Fruquintinib Data With New Minority-Focused Colorectal Cancer Study
PremiumCompany AnnouncementsTakeda Expands Fruquintinib Data With New Minority-Focused Colorectal Cancer Study
1M ago
TAK
Takeda Tracks Real-World Safety of Fruzaqla in South Korean Colorectal Cancer Patients
Premium
Company Announcements
Takeda Tracks Real-World Safety of Fruzaqla in South Korean Colorectal Cancer Patients
1M ago
TAK
Takeda Expands Real-World Evidence for Takhzyro With New Saudi Arabia HAE Study
Premium
Company Announcements
Takeda Expands Real-World Evidence for Takhzyro With New Saudi Arabia HAE Study
1M ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >